意見：STAT+：メディケアの新しいRAPID経路は成人にとってのブレークスルーだが、子供たちはまだ待っている
原題: Opinion: STAT+: Medicare’s new RAPID pathway is a breakthrough for adults. Children are still waiting
分析結果
- カテゴリ
- IT
- 重要度
- 56
- トレンドスコア
- 17
- 要約
- メディケアの新しいRAPID経路は、成人に対して迅速な医療サービスを提供する画期的な取り組みである。しかし、子供たちに対する同様の迅速な対応はまだ実現しておらず、彼らは依然として必要な医療を受けるために長い待機時間を強いられている。この状況は、子供たちの健康と福祉に対する不平等を浮き彫りにしている。
- キーワード
“The pediatric and orphan pipeline is already the smallest, slowest, and least capitalized segment of the device industry,” writes Kolaleh Eskandanian. “The pediatric and orphan pipeline is already the smallest, slowest, and least capitalized segment of the device industry,” writes Kolaleh Eskandanian. In late April, the Centers for Medicare and Medicaid Services and the Food and Drug Administration announced the Regulatory Alignment for Predictable and Immediate Device, or RAPID, coverage pathway . On paper, it is exactly what the medical device community has been asking for: a synchronized process that could deliver Medicare national coverage as soon as two months after FDA market authorization, rather than the year or more families and manufacturers currently endure. I want this pathway to succeed. I have spent more than a decade helping small companies bring novel devices through FDA review, including several that earned breakthrough device designation. I have watched reimbursement delay strangle technologies that children desperately need. Faster, more predictable coverage is a real problem, and RAPID is a real step. But this announcement does not fix the way pediatric and orphan devices chronically lag behind their adult counterparts. In some ways, in fact, it deepens that gap. Continue to STAT+ to read the full story…